2024-02-18 10:03:54 ET
Summary
- Edgewise Therapeutics' stock has rallied massively after receiving FDA designations for its lead asset, EDG-5506, which has a potential $750 million opportunity in BMD.
- The company is focused on developing precision medicines for severe genetic neuromuscular and cardiac disorders.
- Edgewise Therapeutics has recently raised additional capital and has four data readouts for EDG-5506 scheduled for 2024.
- A full investment analysis around Edgewise Therapeutics follows in the paragraphs below.
You don't spread democracy with a barrel of a gun . ? Helen Thomas
Shares of neuromuscular precision medicine concern Edgewise Therapeutics, Inc. ( EWTX ) have rallied very strongly after the FDA assigned Orphan and Rare Pediatric designations to its lead asset EDG-5506. Prior to the surge, net of cash the market was valuing EDG-5506 at ~$100 million, even though early data suggests a decent shot of capturing an unencumbered $750 million opportunity in BMD. With four EDG-5506 data readouts slated for 2024 and enough cash to get it through 2025, this small biotech merited further investigation. An analysis follows below....
Read the full article on Seeking Alpha
For further details see:
Edgewise Therapeutics: Behind The Massive Rally